ABCL:NASDAQ
AbCellera Biologics Inc
$11.93
arrow_upward
+1.10%(+0.13) 1D
$11.90
arrow_downward
-0.25% (-0.030)bedtimeAfter hours
Closed: Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$12.04
High
$12.28
Low
$11.75
Mkt. cap
3.86B
Avg. vol.
5.03M
Volume
3.14M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.41
Shares outstanding
324.05M
No. of employees
562
Open
$12.04
High
$12.28
Low
$11.75
Mkt. cap
3.86B
Avg. vol.
5.03M
Volume
3.14M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.41
Shares outstanding
324.05M
No. of employees
562
News stories
From web sources and news partners
TheStreet
·
1 hour ago
Sam Stovall’s S&P 500 outlook offers hope for 2027
Investing.com
·
4 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
TradingView
·
5 hours ago
There is no fundamental reason for stocks’ reversal, says SA analyst
BigGo Finance
·
1 hour ago
Chip Stocks Rebound; Nasdaq Gains 1.1%, Dow Slips 36 Points
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth care
Websiteabcellera.com